Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Nivolumab

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Nivolumab: Sponsors, patents, clinical trial progress

Nivolumab is an investigational drug.

There have been 787 clinical trials for Nivolumab. The most recent clinical trial was a Phase 2 trial, which was initiated on May 15th 2019.

The most common disease conditions in clinical trials are Carcinoma, Carcinoma, Non-Small-Cell Lung, and Melanoma. The leading clinical trial sponsors are Bristol-Myers Squibb, National Cancer Institute (NCI), and Ono Pharmaceutical Co. Ltd.

There are one hundred US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Nivolumab
CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)Huntsman Cancer InstitutePhase 1/Phase 2
CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)OncoImmune, Inc.Phase 1/Phase 2
Ipilimumab +Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue SarcomaBristol-Myers SquibbPhase 2

See all Nivolumab clinical trials

Clinical Trial Summary for Nivolumab

Top disease conditions for Nivolumab
Top clinical trial sponsors for Nivolumab

See all Nivolumab clinical trials

US Patents for Nivolumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Nivolumab   Start Trial Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC)   Start Trial
Nivolumab   Start Trial Antibody-drug conjugates and immunotoxins Oncomatryx Biopharma, S.L. (Derio, ES)   Start Trial
Nivolumab   Start Trial Predictive test for melanoma patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods Biodesix, Inc. (Boulder, CO)   Start Trial
Nivolumab   Start Trial Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof KANGPU BIOPHARMACEUTICALS, LTD. (Shanghai, CN)   Start Trial
Nivolumab   Start Trial Method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor Amgen Inc. (Thousand Oaks, CA)   Start Trial
Nivolumab   Start Trial Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Bristol-Myers Squibb Company (Princeton, NJ)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Nivolumab

Drugname Country Document Number Estimated Expiration Related US Patent
Nivolumab European Patent Office 3313818 2035-06-26   Start Trial
Nivolumab Japan 2018527302 2035-06-26   Start Trial
Nivolumab World Intellectual Property Organization (WIPO) 2016210262 2035-06-26   Start Trial
Nivolumab Canada 2937600 2034-02-06   Start Trial
Nivolumab China 105980411 2034-02-06   Start Trial
Nivolumab Denmark 3102606 2034-02-06   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.